Please try another search
For the six months ended 30 June 2018, Unipharm AD revenues decreased 12% to BGN9M. Net income decreased 76% to BGN252K. Revenues reflect Sales of Products decrease of 12% to BGN8.8M, Other Sales decrease of 46% to BGN104K. Net income also reflects Income from Financing decrease of 69% to BGN55K (income), Employee Related Expenses increase of 2% to BGN2.5M (expense), Expenses for Insurance increase of 2% to BGN321K (expense).
Period Ending: | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 |
---|---|---|---|---|
Total Revenue | 3.38 | 5.57 | 19.28 | 4.07 |
Gross Profit | 1.36 | 2.55 | 9.32 | 2.33 |
Operating Income | -0.47 | 0.67 | 1.28 | 0.37 |
Net Income | -0.46 | 0.71 | 1.94 | 0.47 |
Period Ending: | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 |
---|---|---|---|---|
Total Assets | 21.3 | 22.61 | 20.58 | 21.18 |
Total Liabilities | 2.73 | 3.54 | 1.87 | 2.58 |
Total Equity | 18.58 | 19.07 | 18.71 | 18.6 |
Period Ending: | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 |
---|---|---|---|---|
Period Length: | 6 Months | 3 Months | 12 Months | 9 Months |
Cash From Operating Activities | 0.01 | -0.17 | 2.04 | 1.18 |
Cash From Investing Activities | -0.18 | -0.08 | -0.85 | -0.57 |
Cash From Financing Activities | -0.07 | -0.06 | -0.51 | -0.43 |
Net Change in Cash | -0.24 | -0.31 | 0.68 | 0.17 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review